Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 124-134

  Hoffmann, H Heinrich ^a,b   Palese, Peter ^a   Shaw, Megan L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

High throughput screen; Influenza; Na+ channel; Protein kinase C

Indexed keywords

2',4' DICHLOROBENZAMIL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DICHLOROBENZAMIL; DIGOXIN; GLYCOSIDE; INOTROPIC AGENT; LANATOSIDE C; MEZEREIN; OUABAIN; PHENAMIL; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; ROTTLERIN; SDZ 201106; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; STROPHANTHIDIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; SODIUM CURRENT; SODIUM TRANSPORT; TISSUE CULTURE; VIROGENESIS; VIRUS REPLICATION;

ANIMALS; CELL LINE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; DOGS; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATORS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; VERO CELLS; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE;

EID: 53249140699     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.05.008     Document Type: Article

References (51)

1. Arora D.J., and Gasse N. Influenza virus hemagglutinin stimulates the protein kinase C activity of human polymorphonuclear leucocytes. Arch. Virol. 143 10 (1998) 2029-2037
2. Blair W.S., Isaacson J., Li X., Cao J., Peng Q., Kong G.F., and Patick A.K. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antiviral Res. 65 2 (2005) 107-116
3. Booth R.E., and Stockand J.D. Targeted degradation of ENaC in response to PKC activation of the ERK1/2 cascade. Am. J. Physiol. Renal Physiol. 284 5 (2003) F938-F947
4. Bright R.A., Shay D.K., Shu B., Cox N.J., and Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295 8 (2006) 891-894
5. Chen X.J., Seth S., Yue G., Kamat P., Compans R.W., Guidot D., Brown L.A., Eaton D.C., and Jain L. Influenza virus inhibits ENaC and lung fluid clearance. Am. J. Physiol. Lung Cell. Mol. Physiol. 287 2 (2004) L366-373
6. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., and Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193 12 (2006) 1626-1629
7. Chu J.J., and Yang P.L. c-Src protein kinase inhibitors block assembly and maturation of dengue virus. Proc. Natl. Acad. Sci. U.S.A. 104 9 (2007) 3520-3525
8. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., and Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 9101 (1998) 472-477
9. Deng L., Dai P., Ciro A., Smee D.F., Djaballah H., and Shuman S. Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J. Virol. 81 24 (2007) 13392-13402
10. Dodson A.W., Taylor T.J., Knipe D.M., and Coen D.M. Inhibitors of the sodium potassium ATPase that impair herpes simplex virus replication identified via a chemical screening approach. Virology 366 2 (2007) 340-348
11. Ewart G.D., Mills K., Cox G.B., and Gage P.W. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur. Biophys. J. 31 1 (2002) 26-35
12. Ewart G.D., Nasr N., Naif H., Cox G.B., Cunningham A.L., and Gage P.W. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages. Antimicrob. Agents Chemother. 48 6 (2004) 2325-2330
13. Fodor E., Devenish L., Engelhardt O.G., Palese P., Brownlee G.G., and Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J. Virol. 73 11 (1999) 9679-9682
14. Garman E., and Laver G. Controlling influenza by inhibiting the virus's neuraminidase. Curr. Drug Targets 5 2 (2004) 119-136
15. Gazina E.V., Harrison D.N., Jefferies M., Tan H., Williams D., Anderson D.A., and Petrou S. Ion transport blockers inhibit human rhinovirus 2 release. Antiviral Res. 67 2 (2005) 98-106
16. Ghosh R.N., DeBiasio R., Hudson C.C., Ramer E.R., Cowan C.L., and Oakley R.H. Quantitative cell-based high-content screening for vasopressin receptor agonists using transfluor technology. J. Biomol. Screen. 10 5 (2005) 476-484
17. Harrison D.N., Gazina E.V., Purcell D.F., Anderson D.A., and Petrou S. Amiloride derivatives inhibit coxsackievirus B3 RNA replication. J. Virol. 82 3 (2008) 1465-1473
18. Hellebrekers D.M., Griffioen A.W., and van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta 1775 1 (2007) 76-91
19. Kleyman T.R., and Cragoe Jr. E.J. The mechanism of actionn of amiloride. Semin. Nephrol. 8 3 (1988) 242-248
20. + channels in respiratory epithelia. Proc. Natl. Acad. Sci. U.S.A. 97 18 (2000) 10282-10287
21. Kurokawa M., Ochiai H., Nakajima K., and Niwayama S. Inhibitory effect of protein kinase C inhibitor on the replication of influenza type A virus. J. Gen. Virol. 71 Pt 9 (1990) 2149-2155
22. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., and Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437 7062 (2005) 1108
23. Matrosovich M., Matrosovich T., Garten W., and Klenk H.D. New low-viscosity overlay medium for viral plaque assays. Virol. J. 3 (2006) 63
24. Nagai Y., Maeno K., Iinuma M., Yoshida T., and Matsumoto T. Inhibition of virus growth by ouabain: effect of ouabain on the growth of HVJ in chick embryo cells. J. Virol. 9 2 (1972) 234-243
25. Neumann G., and Hobom G. Mutational analysis of influenza virus promoter elements in vivo. J. Gen. Virol. 76 Pt 7 (1995) 1709-1717
26. Noah J.W., Severson W., Noah D.L., Rasmussen L., White E.L., and Jonsson C.B. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73 1 (2007) 50-59
27. Oxford J.S., Manuguerra C., Kistner O., Linde A., Kunze M., Lange W., Schweiger B., Spala G., Rebelo de Andrade H., Perez Brena P.R., Beytout J., Brydak L., Caraffa de Stefano D., Hungnes O., Kyncl J., Montomoli E., Gil de Miguel A., Vranckx R., and Osterhaus A. A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. Vaccine 23 46-47 (2005) 5440-5449
28. Palese P., and Shaw M.L. Orthomyxoviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. (2007), Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, USA 1647-1689
29. Pinto L.H., and Lamb R.A. Understanding the mechanism of action of the anti-influenza virus drug amantadine. Trends Microbiol. 3 7 (1995) 271
30. Pleschka S., Jaskunas R., Engelhardt O.G., Zurcher T., Palese P., and Garcia-Sastre A. A plasmid-based reverse genetics system for influenza A virus. J. Virol. 70 6 (1996) 4188-4192
31. Premkumar A., Horan C.R., and Gage P.W. Dengue virus M protein C-terminal peptide (DVM-C) forms ion channels. J. Membr. Biol. 204 1 (2005) 33-38
32. Premkumar A., Wilson L., Ewart G.D., and Gage P.W. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett. 557 1-3 (2004) 99-103
33. Romanova J., Katinger D., Ferko B., Vcelar B., Sereinig S., Kuznetsov O., Stukova M., Erofeeva M., Kiselev O., Katinger H., and Egorov A. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res. 103 1-2 (2004) 187-193
34. Root C.N., Wills E.G., McNair L.L., and Whittaker G.R. Entry of influenza viruses into cells is inhibited by a highly specific protein kinase C inhibitor. J. Gen. Virol. 81 Pt 11 (2000) 2697-2705
35. Rott O., Charreire J., Semichon M., Bismuth G., and Cash E. B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating Ca(2+)-independent mechanism. J. Immunol. 154 5 (1995) 2092-2103
36. Senne D.A., Panigrahy B., Kawaoka Y., Pearson J.E., Suss J., Lipkind M., Kida H., and Webster R.G. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis. 40 2 (1996) 425-437
37. Severson W.E., Shindo N., Sosa M., Fletcher T., White E.L., Ananthan S., and Jonsson C.B. Development and validation of a high-throughput screen for inhibitors of SARS CoV and its application in screening of a 100,000-compound library. J. Biomol. Screen. 12 1 (2007) 33-40
38. Sieczkarski S.B., Brown H.A., and Whittaker G.R. Role of protein kinase C betaII in influenza virus entry via late endosomes. J. Virol. 77 1 (2003) 460-469
39. + channel subunit proteins. J. Biol. Chem. 275 33 (2000) 25760-25765
40. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., Xu X., Lu X., Katz J., Cox N., and Matsuoka Y. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 1 (2003) 192-200
41. Takada A., Kuboki N., Okazaki K., Ninomiya A., Tanaka H., Ozaki H., Itamura S., Nishimura H., Enami M., Tashiro M., Shortridge K.F., and Kida H. Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. J. Virol. 73 10 (1999) 8303-8307
42. Tomita Y., and Kuwata T. Suppression of murine leukaemia virus production by ouabain and interferon in mouse cells. J. Gen. Virol. 38 2 (1978) 223-230
43. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354 13 (2006) 1343-1351
44. Tree J.A., Richardson C., Fooks A.R., Clegg J.C., and Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19 25-26 (2001) 3444-3450
45. Wharton S.A., Belshe R.B., Skehel J.J., and Hay A.J. Role of virion M2 protein in influenza virus uncoating: specific reduction in the rate of membrane fusion between virus and liposomes by amantadine. J. Gen. Virol. 75 Pt 4 (1994) 945-948
46. WHO. 2003. Influenza: Overview. http://www.who.int/mediacentre/factsheets/fs211/en/; March 2003.
47. WHO. 2008. Influenza A(H1N1) virus resistance to oseltamivir. http://www.who.int/csr/disease/influenza/h1n1_table/en/index.html; 02/28/08.
48. Wilson L., Gage P., and Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 353 2 (2006) 294-306
49. + transport and epithelial sodium channel expression by protein kinase C in rat alveolar epithelial cells. Can. J. Physiol. Pharmacol. 83 11 (2005) 977-987
50. Zhang J.H., Chung T.D., and Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 2 (1999) 67-73
51. Zuck P., Murray E.M., Stec E., Grobler J.A., Simon A.J., Strulovici B., Inglese J., Flores O.A., and Ferrer M. A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. Anal. Biochem. 334 2 (2004) 344-355